In this respect, it is worth mentioning that clinical trials in patients with established metastatic disease have shown that endostatin, although well tolerated, generated marginal tumour responses (Eder et al, 2002; Herbst et al, 2002; Thomas et al, 2003). This evidence concerns the gene COL18A1 and neoplasm.